

O I P E
FEB 05 1998 JC22
PATENT & TRADEMARK OFFICE

Attorney Docket No. 230
PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Munger et al.

Serial No.: 08/900,752

Group No.: 1205

Filed: July 25, 1997

Examiner: unassigned

For: NUCLEOTIDE ANALOG COMPOSITION AND SYNTHESIS METHOD

#6
AFP
5.11.98

Assistant Commissioner for Patents

Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT (modified)

List of Sections Forming Part of This Information Disclosure Statement.

The following sections are being submitted for this Information Disclosure Statement:

1. Preliminary Statements
2. FORM PTO - 1449 (Modified)
3. Copies of Listed Information Items Accompanying This Statement

Section 1. Preliminary statements

Applicants submit herewith patents, publications or other information of which they are aware, which they believe may be material to the examination of this application and in respect of which there may be a duty to disclose.

The filing of this information disclosure statement shall not be construed as a representation that a search has been made (37 CFR 1.97 (g)), an admission that the information cited is, or is considered to be, material to patentability or that no other material information exists.

The filing of this information disclosure statement shall not be construed as an admission against interest in any manner. Notice of January 9, 1992, 1135 O.G. 13-25, at 25.

CERTIFICATE OF MAILING

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

Robin Torres


(Type or print name of person mailing paper)

Date:

February 2, 1998

Robin Torres

(Signature of person mailing paper)



**IDENTIFICATION OF TIME OF FILING THE ACCOMPANYING
INFORMATION DISCLOSURE STATEMENT**

The information disclosure statement submitted herewith is being filed within three months of the filing date of the application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever event occurs last. 37 CFR 1.97 (b).

Reg. No. 36,616

Daryl D. Muenchau
SIGNATURE OF AGENT

Tel. No.: (650) 573-4712

Daryl D. Muenchau
Type or print name of agent

Gilead Sciences, Inc.
333 Lakeside Drive
P.O. Address

Foster City, CA 94404

RECEIVED

FEB 17 1998

MAILING ROOM
CENTRAL DIVISION



Attorney Docket No. 230
PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

The application of: Munger et al.

Serial No.: 08/900,752

Group No.: 1205

Filed: July 25, 1997

Examiner: unassigned

For: NUCLEOTIDE ANALOG COMPOSITION AND SYNTHESIS METHOD

Assistant Commissioner for Patents

Washington, D.C. 20231

16C3

RE/1614

FEB 17 1998

MATRIX MAIL CENTER
SERIALS SECTION

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT WITHIN
THREE MONTHS OF FILING OR BEFORE MAILING OF
FIRST OFFICE ACTION (37 CFR 1.97 (b))

CERTIFICATE OF MAILING

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited on the date shown below with the United States Postal Service in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

(check and complete appropriate item below):

37 CFR 1.8 (a)

with sufficient postage as
first class mail

or

37 CFR 1.10

as "Express Mail Post
Office to Addressee" Mailing
Label
No. _____

Robin Torres

(Type or print name of person mailing paper)

Date: February 2, 1998

Robin Torres
(Signature of person mailing paper)

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEINFORMATION DISCLOSURE STATEMENT
BY APPLICANT

(37 CFR 1.98(b))


ATTY DOCKET NO.: 230

SERIAL NO.: 08/900,752

APPLICANT: Munger et al.

FILING DATE: 7/25/97

GROUP ART UNIT: 1205



U.S. PATENT DOCUMENTS

| EXAMR'S INITIALS | PATENT NO. | ISSUE DATE | PATENTEE | CLASS/ SUBCLASS | FILING DATE |
|------------------|------------|------------|----------------------|-----------------|-------------|
| HTD | 5,663,159 | 9/2/97 | Starrett, Jr. et al. | 514/181 | 10/11/94 |

FOREIGN PATENT DOCUMENTS

| EXAMR'S INITIALS | PATENT NO. | PUBLICATION DATE | COUNTRY | CLASS/ SUBCLASS | TRANSLATION YES/NO |
|------------------|--------------|------------------|---------|-----------------|--------------------|
| HTD | 0 481 214 A1 | 4/22/92 | EUROPE | — | |
| HTD | WO 95/07920 | 3/23/95 | PCT | — | |

OTHER DOCUMENTS

| EXAMR'S INITIALS | ARTICLE |
|------------------|---|
| HTD | De Clercq et al., "(S)-9-(2,3-dihydroxypropyl)adenine: An Aliphatic Nucleoside Analog with Broad-Spectrum Antiviral Activity", 200:563-565, SCIENCE, 1978 |
| HTD | Lindahl et al., "Synthesis of an Acyloxymethyl Prodrug of the Inositol Phosphate Alpha-Trinisol", 15(5):549-554, J CARBOHYDRATE CHEMISTRY, 1996 |
| HTD | Samara et al., "Pharmacokinetic Analysis of Diethylcarbonate Prodrugs of Ibuprofen and Naproxen", 16:201-210, Biopharmaceutics & Drug Disposition, 1995 |

EXAMINER

James H. Neuma

DATE CONSIDERED

11/23/98

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.